Welcome

Welcome Maryland and D.C. Society of Clinical Oncology Members to our newly established social media website. The purpose of the website is to encourage communication among the MDCSCO membership on topics that are of interest and importance to our members.

Hot News!
Senate Bill 884: An Act Concerning Prescription Drugs & Dispensing Permits
Click here to view the bill
Click here to discuss the bill

Summary:

  1. restricts a physician from dispensing drugs unless the physician obtains a dispensing permit from the Pharmacy Board
  2. limits dispensing to patients who have no pharmacy within 10 miles of the patients’ homes; and
  3. physician must be on the premises if the physician’s CNP or PA dispenses drugs under the restrictions listed above;
  4. physician is subject to oversight and sanctions by the pharmacy board; and
  5. physician may not have a substantial financial interest in a pharmacy.

Note sections WHICH ARE HIGHLIGHTED IN THE ATTACHMENT:
12-6D-01 (B), 12-6D-02, 12-6D-04 (10), 12-6D-11(A) (2) (1)

Senate Bill assigned to Education Health and Environmental Affairs
Hearing 3/15 at 1:00 p.m.

House bill assigned to Health and Government Operations
Hearing 3/17 at 1:00 p.m.

The mission of the Maryland and District of Columbia Society of Clinical Oncology (MDCSCO) is to improve the quality and delivery of care of medical oncology in Maryland and the District of Columbia, to educate public government and insurance carriers about appropriate prevention of cancer and current therapeutic options for our patients with cancer and to promote appropriate standards of the care of oncology including participation in cancer research.

MDCSCO is undergoing a reorganization to improve our effectiveness. This will include the development of the Practice Committee, the Advocacy Policy Committee and the Program Committee. The Practice Committee is centered around issues related to access to care, for advocacy with regard to Medicare and Medicaid as well as other insurance carriers. The primary focus of this committee is to provide care for all patients for appropriate oncology services as well as reimbursement for these services.

We look forward to increased member participation as well as ideas on new initiatives to make our organization relevant and interesting.

Paul Celano, MD FACP
President, Maryland DC Society of Clinical Oncology

This project was partially funded by a grant from ASCO.

OUR CORPORATE MEMBERS
Diamond Members
Celgene


Platinum Members
Amgen

Cephalon

Onyx

Gold Members
Millenium Pharmaceuticals

Novartis

Eli Lilly Pharmaceuticals

Eli Lilly Pharmaceuticals
 

Silver Members
Caris

Eisai

Genentech

Glaxo Smith Kline